A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients

Abstract Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma (DTC). From December 2015 to May 2019, 689 patients undergone RRA at Nuclear Medicine Department, Second H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan Xiao, Canhua Yun, Jingjia Cao, Shouluan Ding, Chunchun Shao, Lina Wang, Fengyan Huang, Hongying Jia
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d79ca3e2c7a54b23b2de6ae6513254e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d79ca3e2c7a54b23b2de6ae6513254e9
record_format	dspace
spelling	oai:doaj.org-article:d79ca3e2c7a54b23b2de6ae6513254e92021-12-02T14:12:08ZA pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients10.1038/s41598-020-80015-82045-2322https://doaj.org/article/d79ca3e2c7a54b23b2de6ae6513254e92021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80015-8https://doaj.org/toc/2045-2322Abstract Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma (DTC). From December 2015 to May 2019, 689 patients undergone RRA at Nuclear Medicine Department, Second Hospital of Shandong University were included in the study. Patients were categorized by their pre-ablative TSH level grouping of < 30, 30–70 and ≥ 70 mIU/L. Response to RRA were evaluated as complete response (including excellent and indeterminate response) and incomplete response (including biochemical and structural incomplete response) after a follow-up of 6–8 months. Multivariable binary logistic regression model was used to explore the optimum pre-ablative TSH level range and independent factors associated with response to RRA. Rates of complete response to RRA were 63.04%, 74.59% and 66.41% in TSH level groups of < 30, 30–70 and ≥ 70 mIU/L, separately. With multivariate analysis, the study found that pre-ablative TSH levels, gender and lymph node dissection were independent predictors of response to RRA. TSH between 30 and 70 mIU/L had a higher rate of complete response compared with TSH < 30 mIU/L, OR 0.451 (95% CI 0.215–0.958, P = 0.036). A pre-ablative TSH level of 30–70 mIU/L was appropriate for patients with DTC to achieve a better response to RRA.Juan XiaoCanhua YunJingjia CaoShouluan DingChunchun ShaoLina WangFengyan HuangHongying JiaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Juan Xiao Canhua Yun Jingjia Cao Shouluan Ding Chunchun Shao Lina Wang Fengyan Huang Hongying Jia A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
description	Abstract Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma (DTC). From December 2015 to May 2019, 689 patients undergone RRA at Nuclear Medicine Department, Second Hospital of Shandong University were included in the study. Patients were categorized by their pre-ablative TSH level grouping of < 30, 30–70 and ≥ 70 mIU/L. Response to RRA were evaluated as complete response (including excellent and indeterminate response) and incomplete response (including biochemical and structural incomplete response) after a follow-up of 6–8 months. Multivariable binary logistic regression model was used to explore the optimum pre-ablative TSH level range and independent factors associated with response to RRA. Rates of complete response to RRA were 63.04%, 74.59% and 66.41% in TSH level groups of < 30, 30–70 and ≥ 70 mIU/L, separately. With multivariate analysis, the study found that pre-ablative TSH levels, gender and lymph node dissection were independent predictors of response to RRA. TSH between 30 and 70 mIU/L had a higher rate of complete response compared with TSH < 30 mIU/L, OR 0.451 (95% CI 0.215–0.958, P = 0.036). A pre-ablative TSH level of 30–70 mIU/L was appropriate for patients with DTC to achieve a better response to RRA.
format	article
author	Juan Xiao Canhua Yun Jingjia Cao Shouluan Ding Chunchun Shao Lina Wang Fengyan Huang Hongying Jia
author_facet	Juan Xiao Canhua Yun Jingjia Cao Shouluan Ding Chunchun Shao Lina Wang Fengyan Huang Hongying Jia
author_sort	Juan Xiao
title	A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
title_short	A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
title_full	A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
title_fullStr	A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
title_full_unstemmed	A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
title_sort	pre-ablative thyroid-stimulating hormone with 30–70 miu/l achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d79ca3e2c7a54b23b2de6ae6513254e9
work_keys_str_mv	AT juanxiao apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT canhuayun apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT jingjiacao apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT shouluanding apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT chunchunshao apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT linawang apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT fengyanhuang apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT hongyingjia apreablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT juanxiao preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT canhuayun preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT jingjiacao preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT shouluanding preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT chunchunshao preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT linawang preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT fengyanhuang preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients AT hongyingjia preablativethyroidstimulatinghormonewith3070miulachievesbetterresponsetoinitialradioiodineremnantablationindifferentiatedthyroidcarcinomapatients
_version_	1718391815118258176

A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients

Ejemplares similares